Abstract
Serum levels of NSE were monitored in 20 SCLC patients who completely responded to combination chemotherapy. An elevation of NSE was observed in five of nine patients with recurrent disease, but predated a relapse in only one. No elevation in NSE level was noted in nine patients who remained in complete remission. The addition of serial assays of LDH to NSE monitoring did not result in any gain in early warning of relapse. This study suggests that the value of serial NSE measurements for predicting a relapse of disease is limited.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
